nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—L-DOPA—Melphalan—ovarian cancer	0.396	1	CrCrCtD
Mesalazine—MPO—Carboplatin—ovarian cancer	0.141	1	CbGbCtD
Mesalazine—PTGS2—ovarian follicle—ovarian cancer	0.00597	0.0827	CbGeAlD
Mesalazine—PPARG—Irinotecan—Topotecan—ovarian cancer	0.00368	1	CbGdCrCtD
Mesalazine—CHUK—epithelium—ovarian cancer	0.00305	0.0422	CbGeAlD
Mesalazine—PTGS1—oviduct—ovarian cancer	0.00274	0.038	CbGeAlD
Mesalazine—IKBKB—myometrium—ovarian cancer	0.00264	0.0365	CbGeAlD
Mesalazine—IKBKB—embryo—ovarian cancer	0.00254	0.0352	CbGeAlD
Mesalazine—CHUK—female reproductive system—ovarian cancer	0.00226	0.0313	CbGeAlD
Mesalazine—CHUK—female gonad—ovarian cancer	0.00206	0.0285	CbGeAlD
Mesalazine—IKBKB—uterine cervix—ovarian cancer	0.00205	0.0284	CbGeAlD
Mesalazine—IKBKB—decidua—ovarian cancer	0.00196	0.0271	CbGeAlD
Mesalazine—IKBKB—endometrium—ovarian cancer	0.00186	0.0257	CbGeAlD
Mesalazine—CHUK—testis—ovarian cancer	0.00183	0.0253	CbGeAlD
Mesalazine—IKBKB—gonad—ovarian cancer	0.00172	0.0239	CbGeAlD
Mesalazine—IKBKB—uterus—ovarian cancer	0.00171	0.0237	CbGeAlD
Mesalazine—ALOX5—decidua—ovarian cancer	0.00162	0.0225	CbGeAlD
Mesalazine—PPARG—embryo—ovarian cancer	0.00158	0.0219	CbGeAlD
Mesalazine—IKBKB—female reproductive system—ovarian cancer	0.00154	0.0213	CbGeAlD
Mesalazine—MPO—epithelium—ovarian cancer	0.00145	0.0201	CbGeAlD
Mesalazine—IKBKB—female gonad—ovarian cancer	0.0014	0.0194	CbGeAlD
Mesalazine—IKBKB—vagina—ovarian cancer	0.00139	0.0193	CbGeAlD
Mesalazine—CHUK—lymph node—ovarian cancer	0.00132	0.0183	CbGeAlD
Mesalazine—PPARG—epithelium—ovarian cancer	0.00129	0.0179	CbGeAlD
Mesalazine—ALOX5—female reproductive system—ovarian cancer	0.00127	0.0177	CbGeAlD
Mesalazine—IKBKB—testis—ovarian cancer	0.00124	0.0172	CbGeAlD
Mesalazine—PPARG—decidua—ovarian cancer	0.00122	0.0169	CbGeAlD
Mesalazine—ALOX5—bone marrow—ovarian cancer	0.0012	0.0167	CbGeAlD
Mesalazine—ALOX5—female gonad—ovarian cancer	0.00116	0.0161	CbGeAlD
Mesalazine—PPARG—uterus—ovarian cancer	0.00106	0.0148	CbGeAlD
Mesalazine—ALOX5—testis—ovarian cancer	0.00103	0.0143	CbGeAlD
Mesalazine—MPO—bone marrow—ovarian cancer	0.00102	0.0141	CbGeAlD
Mesalazine—PPARG—female reproductive system—ovarian cancer	0.000957	0.0133	CbGeAlD
Mesalazine—PPARG—bone marrow—ovarian cancer	0.000904	0.0125	CbGeAlD
Mesalazine—IKBKB—lymph node—ovarian cancer	0.0009	0.0125	CbGeAlD
Mesalazine—PPARG—female gonad—ovarian cancer	0.000871	0.0121	CbGeAlD
Mesalazine—MPO—testis—ovarian cancer	0.00087	0.0121	CbGeAlD
Mesalazine—PPARG—vagina—ovarian cancer	0.000866	0.012	CbGeAlD
Mesalazine—PTGS2—myometrium—ovarian cancer	0.000839	0.0116	CbGeAlD
Mesalazine—PTGS2—embryo—ovarian cancer	0.000807	0.0112	CbGeAlD
Mesalazine—PPARG—testis—ovarian cancer	0.000772	0.0107	CbGeAlD
Mesalazine—ALOX5—lymph node—ovarian cancer	0.000746	0.0103	CbGeAlD
Mesalazine—PTGS1—epithelium—ovarian cancer	0.000689	0.00954	CbGeAlD
Mesalazine—PTGS1—uterine cervix—ovarian cancer	0.000683	0.00946	CbGeAlD
Mesalazine—PTGS2—epithelium—ovarian cancer	0.000658	0.00912	CbGeAlD
Mesalazine—PTGS2—uterine cervix—ovarian cancer	0.000653	0.00904	CbGeAlD
Mesalazine—MPO—lymph node—ovarian cancer	0.000631	0.00874	CbGeAlD
Mesalazine—PTGS1—endometrium—ovarian cancer	0.000618	0.00856	CbGeAlD
Mesalazine—PTGS2—endometrium—ovarian cancer	0.00059	0.00818	CbGeAlD
Mesalazine—PTGS1—uterus—ovarian cancer	0.000569	0.00789	CbGeAlD
Mesalazine—PPARG—lymph node—ovarian cancer	0.00056	0.00776	CbGeAlD
Mesalazine—PTGS2—uterus—ovarian cancer	0.000544	0.00754	CbGeAlD
Mesalazine—PTGS1—female reproductive system—ovarian cancer	0.000512	0.00709	CbGeAlD
Mesalazine—PTGS2—female reproductive system—ovarian cancer	0.000489	0.00678	CbGeAlD
Mesalazine—PTGS1—female gonad—ovarian cancer	0.000466	0.00645	CbGeAlD
Mesalazine—PTGS1—vagina—ovarian cancer	0.000463	0.00641	CbGeAlD
Mesalazine—PTGS2—bone marrow—ovarian cancer	0.000462	0.0064	CbGeAlD
Mesalazine—PTGS2—female gonad—ovarian cancer	0.000445	0.00617	CbGeAlD
Mesalazine—PTGS2—vagina—ovarian cancer	0.000442	0.00613	CbGeAlD
Mesalazine—PTGS1—testis—ovarian cancer	0.000413	0.00572	CbGeAlD
Mesalazine—PTGS1—lymph node—ovarian cancer	0.000299	0.00415	CbGeAlD
Mesalazine—PTGS2—lymph node—ovarian cancer	0.000286	0.00396	CbGeAlD
Mesalazine—Neutropenia—Doxorubicin—ovarian cancer	7.69e-05	0.000364	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—ovarian cancer	7.69e-05	0.000364	CcSEcCtD
Mesalazine—Decreased appetite—Paclitaxel—ovarian cancer	7.68e-05	0.000364	CcSEcCtD
Mesalazine—Dry mouth—Docetaxel—ovarian cancer	7.64e-05	0.000362	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	7.64e-05	0.000362	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.63e-05	0.000361	CcSEcCtD
Mesalazine—Fatigue—Paclitaxel—ovarian cancer	7.62e-05	0.000361	CcSEcCtD
Mesalazine—Sweating—Epirubicin—ovarian cancer	7.6e-05	0.00036	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—ovarian cancer	7.6e-05	0.00036	CcSEcCtD
Mesalazine—Pain—Paclitaxel—ovarian cancer	7.56e-05	0.000358	CcSEcCtD
Mesalazine—Constipation—Paclitaxel—ovarian cancer	7.56e-05	0.000358	CcSEcCtD
Mesalazine—Haematuria—Epirubicin—ovarian cancer	7.55e-05	0.000358	CcSEcCtD
Mesalazine—Confusional state—Docetaxel—ovarian cancer	7.55e-05	0.000358	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.51e-05	0.000355	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—ovarian cancer	7.49e-05	0.000355	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—ovarian cancer	7.49e-05	0.000355	CcSEcCtD
Mesalazine—Oedema—Docetaxel—ovarian cancer	7.49e-05	0.000355	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—ovarian cancer	7.48e-05	0.000354	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—ovarian cancer	7.47e-05	0.000354	CcSEcCtD
Mesalazine—Infection—Docetaxel—ovarian cancer	7.44e-05	0.000352	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—ovarian cancer	7.44e-05	0.000352	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—ovarian cancer	7.43e-05	0.000352	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—ovarian cancer	7.39e-05	0.00035	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—ovarian cancer	7.37e-05	0.000349	CcSEcCtD
Mesalazine—Shock—Docetaxel—ovarian cancer	7.37e-05	0.000349	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—ovarian cancer	7.35e-05	0.000348	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—ovarian cancer	7.34e-05	0.000347	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—ovarian cancer	7.33e-05	0.000347	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—ovarian cancer	7.33e-05	0.000347	CcSEcCtD
Mesalazine—Tachycardia—Docetaxel—ovarian cancer	7.31e-05	0.000346	CcSEcCtD
Mesalazine—Feeling abnormal—Paclitaxel—ovarian cancer	7.28e-05	0.000345	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—ovarian cancer	7.28e-05	0.000345	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.27e-05	0.000344	CcSEcCtD
Mesalazine—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.23e-05	0.000342	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—ovarian cancer	7.21e-05	0.000341	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.19e-05	0.00034	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—ovarian cancer	7.15e-05	0.000338	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—ovarian cancer	7.15e-05	0.000338	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—ovarian cancer	7.15e-05	0.000338	CcSEcCtD
Mesalazine—Anorexia—Docetaxel—ovarian cancer	7.14e-05	0.000338	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—ovarian cancer	7.13e-05	0.000338	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—ovarian cancer	7.13e-05	0.000337	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—ovarian cancer	7.13e-05	0.000337	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—ovarian cancer	7.11e-05	0.000337	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—ovarian cancer	7.11e-05	0.000337	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—ovarian cancer	7.06e-05	0.000334	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—ovarian cancer	7.03e-05	0.000333	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—ovarian cancer	7.02e-05	0.000333	CcSEcCtD
Mesalazine—Urticaria—Paclitaxel—ovarian cancer	7.02e-05	0.000332	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—ovarian cancer	7.01e-05	0.000332	CcSEcCtD
Mesalazine—Hypotension—Docetaxel—ovarian cancer	7e-05	0.000331	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—ovarian cancer	6.99e-05	0.000331	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—ovarian cancer	6.99e-05	0.000331	CcSEcCtD
Mesalazine—Body temperature increased—Paclitaxel—ovarian cancer	6.99e-05	0.000331	CcSEcCtD
Mesalazine—Abdominal pain—Paclitaxel—ovarian cancer	6.99e-05	0.000331	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—ovarian cancer	6.97e-05	0.00033	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.93e-05	0.000328	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—ovarian cancer	6.92e-05	0.000327	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—ovarian cancer	6.88e-05	0.000326	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—ovarian cancer	6.84e-05	0.000324	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.83e-05	0.000323	CcSEcCtD
Mesalazine—Insomnia—Docetaxel—ovarian cancer	6.78e-05	0.000321	CcSEcCtD
Mesalazine—Paraesthesia—Docetaxel—ovarian cancer	6.73e-05	0.000319	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—ovarian cancer	6.73e-05	0.000318	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—ovarian cancer	6.68e-05	0.000316	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—ovarian cancer	6.66e-05	0.000315	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—ovarian cancer	6.65e-05	0.000315	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—ovarian cancer	6.63e-05	0.000314	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—ovarian cancer	6.61e-05	0.000313	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—ovarian cancer	6.6e-05	0.000313	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—ovarian cancer	6.6e-05	0.000312	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—ovarian cancer	6.6e-05	0.000312	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—ovarian cancer	6.58e-05	0.000312	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—ovarian cancer	6.58e-05	0.000312	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—ovarian cancer	6.53e-05	0.000309	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—ovarian cancer	6.51e-05	0.000308	CcSEcCtD
Mesalazine—Hypersensitivity—Paclitaxel—ovarian cancer	6.51e-05	0.000308	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—ovarian cancer	6.5e-05	0.000308	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—ovarian cancer	6.48e-05	0.000307	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.47e-05	0.000306	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—ovarian cancer	6.47e-05	0.000306	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—ovarian cancer	6.46e-05	0.000306	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—ovarian cancer	6.45e-05	0.000306	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—ovarian cancer	6.45e-05	0.000305	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—ovarian cancer	6.42e-05	0.000304	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—ovarian cancer	6.41e-05	0.000304	CcSEcCtD
Mesalazine—Pain—Docetaxel—ovarian cancer	6.41e-05	0.000303	CcSEcCtD
Mesalazine—Constipation—Docetaxel—ovarian cancer	6.41e-05	0.000303	CcSEcCtD
Mesalazine—Chills—Epirubicin—ovarian cancer	6.38e-05	0.000302	CcSEcCtD
Mesalazine—Asthenia—Paclitaxel—ovarian cancer	6.34e-05	0.0003	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—ovarian cancer	6.29e-05	0.000298	CcSEcCtD
Mesalazine—Pruritus—Paclitaxel—ovarian cancer	6.25e-05	0.000296	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—ovarian cancer	6.23e-05	0.000295	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—ovarian cancer	6.22e-05	0.000295	CcSEcCtD
Mesalazine—Erythema—Epirubicin—ovarian cancer	6.19e-05	0.000293	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—ovarian cancer	6.17e-05	0.000292	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—ovarian cancer	6.15e-05	0.000291	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—ovarian cancer	6.14e-05	0.000291	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—ovarian cancer	6.13e-05	0.00029	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—ovarian cancer	6.11e-05	0.000289	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—ovarian cancer	6.1e-05	0.000289	CcSEcCtD
Mesalazine—Tension—Epirubicin—ovarian cancer	6.08e-05	0.000288	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—ovarian cancer	6.06e-05	0.000287	CcSEcCtD
Mesalazine—Diarrhoea—Paclitaxel—ovarian cancer	6.05e-05	0.000286	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—ovarian cancer	6.01e-05	0.000285	CcSEcCtD
Mesalazine—Back pain—Epirubicin—ovarian cancer	5.99e-05	0.000284	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—ovarian cancer	5.97e-05	0.000283	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—ovarian cancer	5.95e-05	0.000282	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—ovarian cancer	5.94e-05	0.000281	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—ovarian cancer	5.93e-05	0.000281	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—ovarian cancer	5.92e-05	0.00028	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—ovarian cancer	5.92e-05	0.00028	CcSEcCtD
Mesalazine—Chills—Doxorubicin—ovarian cancer	5.91e-05	0.00028	CcSEcCtD
Mesalazine—Dizziness—Paclitaxel—ovarian cancer	5.85e-05	0.000277	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—ovarian cancer	5.84e-05	0.000276	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—ovarian cancer	5.82e-05	0.000275	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—ovarian cancer	5.77e-05	0.000273	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—ovarian cancer	5.75e-05	0.000272	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—ovarian cancer	5.73e-05	0.000271	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—ovarian cancer	5.72e-05	0.000271	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—ovarian cancer	5.65e-05	0.000267	CcSEcCtD
Mesalazine—Tension—Doxorubicin—ovarian cancer	5.62e-05	0.000266	CcSEcCtD
Mesalazine—Vomiting—Paclitaxel—ovarian cancer	5.62e-05	0.000266	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—ovarian cancer	5.61e-05	0.000266	CcSEcCtD
Mesalazine—Malaise—Epirubicin—ovarian cancer	5.58e-05	0.000264	CcSEcCtD
Mesalazine—Rash—Paclitaxel—ovarian cancer	5.57e-05	0.000264	CcSEcCtD
Mesalazine—Dermatitis—Paclitaxel—ovarian cancer	5.57e-05	0.000264	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—ovarian cancer	5.56e-05	0.000263	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—ovarian cancer	5.56e-05	0.000263	CcSEcCtD
Mesalazine—Syncope—Epirubicin—ovarian cancer	5.55e-05	0.000263	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—ovarian cancer	5.54e-05	0.000262	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—ovarian cancer	5.54e-05	0.000262	CcSEcCtD
Mesalazine—Headache—Paclitaxel—ovarian cancer	5.54e-05	0.000262	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—ovarian cancer	5.52e-05	0.000261	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—ovarian cancer	5.51e-05	0.000261	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—ovarian cancer	5.47e-05	0.000259	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—ovarian cancer	5.44e-05	0.000258	CcSEcCtD
Mesalazine—Cough—Epirubicin—ovarian cancer	5.4e-05	0.000256	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—ovarian cancer	5.4e-05	0.000256	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—ovarian cancer	5.38e-05	0.000255	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—ovarian cancer	5.35e-05	0.000253	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—ovarian cancer	5.32e-05	0.000252	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—ovarian cancer	5.3e-05	0.000251	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—ovarian cancer	5.3e-05	0.000251	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—ovarian cancer	5.27e-05	0.00025	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—ovarian cancer	5.27e-05	0.00025	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—ovarian cancer	5.27e-05	0.00025	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—ovarian cancer	5.25e-05	0.000249	CcSEcCtD
Mesalazine—Nausea—Paclitaxel—ovarian cancer	5.25e-05	0.000249	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.24e-05	0.000248	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—ovarian cancer	5.21e-05	0.000247	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—ovarian cancer	5.17e-05	0.000245	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—ovarian cancer	5.16e-05	0.000244	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—ovarian cancer	5.15e-05	0.000244	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—ovarian cancer	5.14e-05	0.000243	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—ovarian cancer	5.13e-05	0.000243	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—ovarian cancer	5.13e-05	0.000243	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—ovarian cancer	5.1e-05	0.000241	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—ovarian cancer	5.06e-05	0.00024	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—ovarian cancer	5.05e-05	0.000239	CcSEcCtD
Mesalazine—Oedema—Epirubicin—ovarian cancer	5.05e-05	0.000239	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—ovarian cancer	5.04e-05	0.000238	CcSEcCtD
Mesalazine—Infection—Epirubicin—ovarian cancer	5.02e-05	0.000238	CcSEcCtD
Mesalazine—Cough—Doxorubicin—ovarian cancer	5e-05	0.000237	CcSEcCtD
Mesalazine—Shock—Epirubicin—ovarian cancer	4.97e-05	0.000235	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—ovarian cancer	4.96e-05	0.000235	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—ovarian cancer	4.95e-05	0.000235	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—ovarian cancer	4.95e-05	0.000234	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—ovarian cancer	4.95e-05	0.000234	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—ovarian cancer	4.93e-05	0.000234	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—ovarian cancer	4.91e-05	0.000232	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—ovarian cancer	4.89e-05	0.000231	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—ovarian cancer	4.88e-05	0.000231	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—ovarian cancer	4.88e-05	0.000231	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—ovarian cancer	4.88e-05	0.000231	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—ovarian cancer	4.86e-05	0.00023	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.84e-05	0.000229	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—ovarian cancer	4.82e-05	0.000228	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—ovarian cancer	4.82e-05	0.000228	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—ovarian cancer	4.77e-05	0.000226	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—ovarian cancer	4.76e-05	0.000226	CcSEcCtD
Mesalazine—Rash—Docetaxel—ovarian cancer	4.72e-05	0.000224	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—ovarian cancer	4.72e-05	0.000224	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—ovarian cancer	4.72e-05	0.000223	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—ovarian cancer	4.71e-05	0.000223	CcSEcCtD
Mesalazine—Headache—Docetaxel—ovarian cancer	4.69e-05	0.000222	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—ovarian cancer	4.68e-05	0.000221	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—ovarian cancer	4.68e-05	0.000221	CcSEcCtD
Mesalazine—Infection—Doxorubicin—ovarian cancer	4.65e-05	0.00022	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.6e-05	0.000218	CcSEcCtD
Mesalazine—Shock—Doxorubicin—ovarian cancer	4.6e-05	0.000218	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—ovarian cancer	4.59e-05	0.000217	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—ovarian cancer	4.58e-05	0.000217	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—ovarian cancer	4.57e-05	0.000216	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—ovarian cancer	4.56e-05	0.000216	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—ovarian cancer	4.54e-05	0.000215	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—ovarian cancer	4.54e-05	0.000215	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—ovarian cancer	4.52e-05	0.000214	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—ovarian cancer	4.51e-05	0.000213	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—ovarian cancer	4.49e-05	0.000213	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—ovarian cancer	4.46e-05	0.000211	CcSEcCtD
Mesalazine—Nausea—Docetaxel—ovarian cancer	4.45e-05	0.000211	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—ovarian cancer	4.45e-05	0.000211	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—ovarian cancer	4.39e-05	0.000208	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—ovarian cancer	4.37e-05	0.000207	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.36e-05	0.000207	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—ovarian cancer	4.36e-05	0.000206	CcSEcCtD
Mesalazine—Pain—Epirubicin—ovarian cancer	4.32e-05	0.000205	CcSEcCtD
Mesalazine—Constipation—Epirubicin—ovarian cancer	4.32e-05	0.000205	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.26e-05	0.000202	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—ovarian cancer	4.23e-05	0.0002	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—ovarian cancer	4.2e-05	0.000199	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—ovarian cancer	4.17e-05	0.000197	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—ovarian cancer	4.16e-05	0.000197	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—ovarian cancer	4.16e-05	0.000197	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—ovarian cancer	4.13e-05	0.000196	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—ovarian cancer	4.12e-05	0.000195	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—ovarian cancer	4.06e-05	0.000192	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.04e-05	0.000191	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—ovarian cancer	4.03e-05	0.000191	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—ovarian cancer	4.01e-05	0.00019	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—ovarian cancer	4e-05	0.000189	CcSEcCtD
Mesalazine—Pain—Doxorubicin—ovarian cancer	4e-05	0.000189	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—ovarian cancer	3.99e-05	0.000189	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—ovarian cancer	3.99e-05	0.000189	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—ovarian cancer	3.85e-05	0.000182	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.82e-05	0.000181	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—ovarian cancer	3.72e-05	0.000176	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—ovarian cancer	3.71e-05	0.000176	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—ovarian cancer	3.7e-05	0.000175	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—ovarian cancer	3.7e-05	0.000175	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—ovarian cancer	3.63e-05	0.000172	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—ovarian cancer	3.58e-05	0.000169	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—ovarian cancer	3.46e-05	0.000164	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—ovarian cancer	3.44e-05	0.000163	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—ovarian cancer	3.35e-05	0.000159	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—ovarian cancer	3.34e-05	0.000158	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—ovarian cancer	3.31e-05	0.000157	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—ovarian cancer	3.21e-05	0.000152	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—ovarian cancer	3.2e-05	0.000151	CcSEcCtD
Mesalazine—Rash—Epirubicin—ovarian cancer	3.19e-05	0.000151	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—ovarian cancer	3.18e-05	0.000151	CcSEcCtD
Mesalazine—Headache—Epirubicin—ovarian cancer	3.17e-05	0.00015	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—ovarian cancer	3.09e-05	0.000146	CcSEcCtD
Mesalazine—Nausea—Epirubicin—ovarian cancer	3e-05	0.000142	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—ovarian cancer	2.97e-05	0.000141	CcSEcCtD
Mesalazine—Rash—Doxorubicin—ovarian cancer	2.95e-05	0.00014	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—ovarian cancer	2.95e-05	0.000139	CcSEcCtD
Mesalazine—Headache—Doxorubicin—ovarian cancer	2.93e-05	0.000139	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—ovarian cancer	2.78e-05	0.000132	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—EGFR—ovarian cancer	1.58e-05	8.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.57e-05	8.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TERT—ovarian cancer	1.55e-05	8.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—ovarian cancer	1.54e-05	8.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR4—ovarian cancer	1.54e-05	8.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PARP1—ovarian cancer	1.53e-05	8.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1B—ovarian cancer	1.52e-05	8.66e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—FASN—ovarian cancer	1.51e-05	8.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—ovarian cancer	1.5e-05	8.52e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—ovarian cancer	1.49e-05	8.48e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC5A5—ovarian cancer	1.48e-05	8.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—ovarian cancer	1.47e-05	8.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6ST—ovarian cancer	1.47e-05	8.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—YAP1—ovarian cancer	1.47e-05	8.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—ovarian cancer	1.46e-05	8.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.45e-05	8.28e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CB—ovarian cancer	1.44e-05	8.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—ovarian cancer	1.43e-05	8.17e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC2A1—ovarian cancer	1.43e-05	8.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CAV1—ovarian cancer	1.43e-05	8.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FASN—ovarian cancer	1.43e-05	8.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PARP1—ovarian cancer	1.42e-05	8.11e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.4e-05	8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—ovarian cancer	1.4e-05	7.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR4—ovarian cancer	1.39e-05	7.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—ovarian cancer	1.38e-05	7.84e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1B1—ovarian cancer	1.37e-05	7.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK3—ovarian cancer	1.37e-05	7.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PPP2R1A—ovarian cancer	1.37e-05	7.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A1—ovarian cancer	1.36e-05	7.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6ST—ovarian cancer	1.36e-05	7.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6ST—ovarian cancer	1.33e-05	7.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.33e-05	7.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK1—ovarian cancer	1.31e-05	7.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—ovarian cancer	1.31e-05	7.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APC—ovarian cancer	1.31e-05	7.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—ovarian cancer	1.3e-05	7.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—ovarian cancer	1.3e-05	7.41e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CAV1—ovarian cancer	1.28e-05	7.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.28e-05	7.28e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—ovarian cancer	1.27e-05	7.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—ovarian cancer	1.26e-05	7.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—ovarian cancer	1.25e-05	7.11e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—ovarian cancer	1.25e-05	7.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK3—ovarian cancer	1.25e-05	7.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CD—ovarian cancer	1.24e-05	7.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PPP2R1A—ovarian cancer	1.24e-05	7.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—ovarian cancer	1.23e-05	7.03e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.22e-05	6.96e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPP2R1A—ovarian cancer	1.22e-05	6.94e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.21e-05	6.91e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—ovarian cancer	1.21e-05	6.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—FASN—ovarian cancer	1.2e-05	6.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—ovarian cancer	1.19e-05	6.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK1—ovarian cancer	1.19e-05	6.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—ovarian cancer	1.19e-05	6.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—ovarian cancer	1.18e-05	6.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC5A5—ovarian cancer	1.18e-05	6.71e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CG—ovarian cancer	1.17e-05	6.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PPP2R1A—ovarian cancer	1.16e-05	6.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CD—ovarian cancer	1.15e-05	6.54e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A1—ovarian cancer	1.14e-05	6.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—ovarian cancer	1.14e-05	6.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—ovarian cancer	1.13e-05	6.46e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCB1—ovarian cancer	1.13e-05	6.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CD—ovarian cancer	1.13e-05	6.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—ovarian cancer	1.12e-05	6.38e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—ovarian cancer	1.12e-05	6.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.11e-05	6.35e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—ovarian cancer	1.11e-05	6.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—ovarian cancer	1.1e-05	6.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1B1—ovarian cancer	1.09e-05	6.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—ovarian cancer	1.09e-05	6.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—ovarian cancer	1.09e-05	6.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—ovarian cancer	1.08e-05	6.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MTOR—ovarian cancer	1.08e-05	6.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—ovarian cancer	1.08e-05	6.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—ovarian cancer	1.05e-05	5.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—ovarian cancer	1.03e-05	5.86e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—ovarian cancer	1.02e-05	5.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—ovarian cancer	1.02e-05	5.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—ovarian cancer	1.01e-05	5.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—ovarian cancer	1.01e-05	5.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—ovarian cancer	1e-05	5.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—ovarian cancer	1e-05	5.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—ovarian cancer	1e-05	5.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—ovarian cancer	1e-05	5.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—ovarian cancer	9.96e-06	5.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—ovarian cancer	9.95e-06	5.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—ovarian cancer	9.88e-06	5.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—ovarian cancer	9.84e-06	5.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—ovarian cancer	9.83e-06	5.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—ovarian cancer	9.83e-06	5.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPP2R1A—ovarian cancer	9.68e-06	5.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—ovarian cancer	9.68e-06	5.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.63e-06	5.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—ovarian cancer	9.61e-06	5.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6ST—ovarian cancer	9.52e-06	5.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—ovarian cancer	9.52e-06	5.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—ovarian cancer	9.39e-06	5.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—ovarian cancer	9.37e-06	5.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—ovarian cancer	9.27e-06	5.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—ovarian cancer	9.22e-06	5.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—ovarian cancer	9.18e-06	5.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—ovarian cancer	9.15e-06	5.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—ovarian cancer	9.15e-06	5.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—ovarian cancer	9.14e-06	5.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—ovarian cancer	9.11e-06	5.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—ovarian cancer	9.1e-06	5.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—ovarian cancer	9.03e-06	5.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—ovarian cancer	8.99e-06	5.12e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—ovarian cancer	8.96e-06	5.1e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—ovarian cancer	8.93e-06	5.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—ovarian cancer	8.9e-06	5.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—ovarian cancer	8.87e-06	5.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—ovarian cancer	8.83e-06	5.03e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—ovarian cancer	8.79e-06	5.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—ovarian cancer	8.77e-06	5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—ovarian cancer	8.71e-06	4.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—ovarian cancer	8.65e-06	4.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6ST—ovarian cancer	8.63e-06	4.91e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.56e-06	4.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—ovarian cancer	8.49e-06	4.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—ovarian cancer	8.49e-06	4.84e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—ovarian cancer	8.48e-06	4.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—ovarian cancer	8.4e-06	4.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—ovarian cancer	8.38e-06	4.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—ovarian cancer	8.36e-06	4.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—ovarian cancer	8.29e-06	4.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—ovarian cancer	8.29e-06	4.72e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—ovarian cancer	8.24e-06	4.69e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—ovarian cancer	8.16e-06	4.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—ovarian cancer	8.07e-06	4.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6ST—ovarian cancer	8.05e-06	4.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—ovarian cancer	8.04e-06	4.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—ovarian cancer	8e-06	4.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—ovarian cancer	7.74e-06	4.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—ovarian cancer	7.73e-06	4.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—ovarian cancer	7.72e-06	4.39e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—ovarian cancer	7.71e-06	4.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—ovarian cancer	7.62e-06	4.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—ovarian cancer	7.61e-06	4.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—ovarian cancer	7.6e-06	4.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—ovarian cancer	7.58e-06	4.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—ovarian cancer	7.39e-06	4.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—ovarian cancer	7.29e-06	4.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—ovarian cancer	7.26e-06	4.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—ovarian cancer	7.19e-06	4.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—ovarian cancer	7.19e-06	4.09e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—ovarian cancer	7.18e-06	4.09e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—ovarian cancer	7.17e-06	4.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—ovarian cancer	7.11e-06	4.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—ovarian cancer	7.1e-06	4.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—ovarian cancer	7.03e-06	4e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—ovarian cancer	7.03e-06	4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—ovarian cancer	7.01e-06	3.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—ovarian cancer	7.01e-06	3.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—ovarian cancer	6.9e-06	3.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—ovarian cancer	6.9e-06	3.93e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—ovarian cancer	6.8e-06	3.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.8e-06	3.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—ovarian cancer	6.73e-06	3.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—ovarian cancer	6.64e-06	3.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—ovarian cancer	6.61e-06	3.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—ovarian cancer	6.58e-06	3.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—ovarian cancer	6.52e-06	3.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—ovarian cancer	6.48e-06	3.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—ovarian cancer	6.45e-06	3.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—ovarian cancer	6.44e-06	3.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—ovarian cancer	6.44e-06	3.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—ovarian cancer	6.35e-06	3.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—ovarian cancer	6.35e-06	3.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—ovarian cancer	6.27e-06	3.57e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—ovarian cancer	6.25e-06	3.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—ovarian cancer	6.21e-06	3.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—ovarian cancer	6.11e-06	3.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—ovarian cancer	6.11e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—ovarian cancer	6.1e-06	3.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—ovarian cancer	6.09e-06	3.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—ovarian cancer	6.06e-06	3.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—ovarian cancer	6.01e-06	3.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—ovarian cancer	5.99e-06	3.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—ovarian cancer	5.96e-06	3.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—ovarian cancer	5.93e-06	3.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—ovarian cancer	5.93e-06	3.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—ovarian cancer	5.85e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—ovarian cancer	5.84e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—ovarian cancer	5.84e-06	3.32e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—ovarian cancer	5.72e-06	3.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—ovarian cancer	5.7e-06	3.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—ovarian cancer	5.69e-06	3.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—ovarian cancer	5.64e-06	3.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—ovarian cancer	5.63e-06	3.21e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—ovarian cancer	5.56e-06	3.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—ovarian cancer	5.54e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—ovarian cancer	5.52e-06	3.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—ovarian cancer	5.49e-06	3.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—ovarian cancer	5.47e-06	3.11e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—ovarian cancer	5.44e-06	3.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—ovarian cancer	5.42e-06	3.08e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—ovarian cancer	5.4e-06	3.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—ovarian cancer	5.4e-06	3.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—ovarian cancer	5.4e-06	3.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—ovarian cancer	5.4e-06	3.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—ovarian cancer	5.31e-06	3.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—ovarian cancer	5.26e-06	2.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—ovarian cancer	5.17e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—ovarian cancer	5.12e-06	2.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—ovarian cancer	5.03e-06	2.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—ovarian cancer	4.98e-06	2.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—ovarian cancer	4.96e-06	2.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—ovarian cancer	4.96e-06	2.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—ovarian cancer	4.92e-06	2.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—ovarian cancer	4.92e-06	2.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—ovarian cancer	4.91e-06	2.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—ovarian cancer	4.9e-06	2.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—ovarian cancer	4.89e-06	2.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—ovarian cancer	4.69e-06	2.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—ovarian cancer	4.65e-06	2.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—ovarian cancer	4.58e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—ovarian cancer	4.57e-06	2.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—ovarian cancer	4.56e-06	2.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—ovarian cancer	4.46e-06	2.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—ovarian cancer	4.46e-06	2.54e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—ovarian cancer	4.45e-06	2.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—ovarian cancer	4.38e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—ovarian cancer	4.29e-06	2.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—ovarian cancer	4.27e-06	2.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—ovarian cancer	4.26e-06	2.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—ovarian cancer	4.22e-06	2.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—ovarian cancer	4.16e-06	2.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—ovarian cancer	4.16e-06	2.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—ovarian cancer	4.13e-06	2.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—ovarian cancer	3.95e-06	2.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—ovarian cancer	3.93e-06	2.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—ovarian cancer	3.87e-06	2.21e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—ovarian cancer	3.81e-06	2.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—ovarian cancer	3.78e-06	2.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—ovarian cancer	3.75e-06	2.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—ovarian cancer	3.61e-06	2.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—ovarian cancer	3.58e-06	2.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—ovarian cancer	3.49e-06	1.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—ovarian cancer	3.43e-06	1.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—ovarian cancer	3.34e-06	1.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—ovarian cancer	3.2e-06	1.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—ovarian cancer	3.16e-06	1.8e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—ovarian cancer	3.11e-06	1.77e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—ovarian cancer	3.03e-06	1.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—ovarian cancer	2.95e-06	1.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—ovarian cancer	2.47e-06	1.41e-05	CbGpPWpGaD
